These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20510459)

  • 1. Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release.
    Trivedi MH; Dunner DL; Kornstein SG; Thase ME; Zajecka JM; Rothschild AJ; Friedman ES; Shelton RC; Keller MB; Kocsis JH; Gelenberg A
    J Affect Disord; 2010 Nov; 126(3):420-9. PubMed ID: 20510459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
    Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen RD; Yan B; Ahmed S; Musgnung J; Ninan PT
    J Clin Psychiatry; 2007 Aug; 68(8):1246-56. PubMed ID: 17854250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term function and psychosocial outcomes with venlafaxine extended release 75-225 mg/day versus placebo in the PREVENT study.
    Watanabe K; Thase ME; Kikuchi T; Tsuboi T; Asami Y; Pappadopulos E; Zhang M; Boucher M; Kornstein S
    Int Clin Psychopharmacol; 2017 Sep; 32(5):271-280. PubMed ID: 28598899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.
    Kornstein SG; Kocsis JH; Ahmed S; Thase M; Friedman ES; Dunlop BW; Yan B; Pedersen R; Ninan PT; Li T; Keller M
    Int Clin Psychopharmacol; 2008 Nov; 23(6):357-63. PubMed ID: 18854724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
    Kornstein SG; Pedersen RD; Holland PJ; Nemeroff CB; Rothschild AJ; Thase ME; Trivedi MH; Ninan PT; Keller MB
    J Clin Psychiatry; 2014 Jan; 75(1):62-8. PubMed ID: 24345717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond remission: rationale and design of the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study.
    Kornstein SG
    CNS Spectr; 2006 Dec; 11(12 Suppl 15):28-34. PubMed ID: 17146416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient outcomes with education, drug therapy, and support: a study of venlafaxine ER-treated outpatients with major depressive disorder.
    Lobello K; Reddy S; Musgnung J; Pedersen R; Ninan PT
    Psychopharmacol Bull; 2010; 43(2):28-44. PubMed ID: 21052041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study.
    Kocsis JH; Thase ME; Trivedi MH; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Dunner DL; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen RD; Yan B; Ahmed S; Musgnung J; Ninan PT; Keller MB
    J Clin Psychiatry; 2007 Jul; 68(7):1014-23. PubMed ID: 17685736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorder.
    Thase M; Asami Y; Wajsbrot D; Dorries K; Boucher M; Pappadopulos E
    Curr Med Res Opin; 2017 Feb; 33(2):317-326. PubMed ID: 27794623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.
    Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL; Dunlop BW; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen R; Yan B; Ahmed S; Schmidt M; Ninan PT
    Biol Psychiatry; 2007 Dec; 62(12):1371-9. PubMed ID: 17825800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study.
    Davidson J; Rothbaum BO; Tucker P; Asnis G; Benattia I; Musgnung JJ
    J Clin Psychopharmacol; 2006 Jun; 26(3):259-67. PubMed ID: 16702890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.
    Thase ME; Gelenberg A; Kornstein SG; Kocsis JH; Trivedi MH; Ninan P; Li T; Pedersen R; Keller M
    J Psychiatr Res; 2011 Mar; 45(3):412-20. PubMed ID: 20801464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
    JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
    Simon JS; Aguiar LM; Kunz NR; Lei D
    J Psychiatr Res; 2004; 38(3):249-57. PubMed ID: 15003430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder.
    Rickels K; Mangano R; Khan A
    J Clin Psychopharmacol; 2004 Oct; 24(5):488-96. PubMed ID: 15349004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study.
    Kornstein SG
    Expert Rev Neurother; 2008 May; 8(5):737-42. PubMed ID: 18457530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies.
    Thase ME; Shelton RC; Khan A
    J Clin Psychopharmacol; 2006 Jun; 26(3):250-8. PubMed ID: 16702889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group.
    Cunningham LA
    Ann Clin Psychiatry; 1997 Sep; 9(3):157-64. PubMed ID: 9339881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.